Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program Shown to Significantly Preserve Vision and Central Retinal Photoreceptors Critical for Visual Acuity Enrollment of Phase 3 ARCHER II Trial Expected to be Completed in Q3 2025, with Topline Data Expected in Second Half of 2026 BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIR ...

Annexon (ANNX) 2025 Conference June 04, 2025 08:10 AM ET Speaker0 My name is Andrew Tsai, senior biotech analyst at Jefferies. Thanks for coming to our day one of the June Healthcare Conference. And it's my pleasure to have to my right Doug Love, CEO of Inexon. Welcome, Doug. Speaker1 Thank you. Speaker0 And maybe to start, give us an introduction about Inexon briefly. I do have a lot of questions for you. But what are you trying to achieve? And just walk us briefly through your milestones over the next six ...

BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:10 a.m. EST. A live webcast of the event can be accessed ...

First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations Poster Presentations on New Pivotal Phase 3 Analyses Underscore Tanruprubart’s Rapid and Sustained Treatment Effect and Improvement in Quality of Life Compared to Placebo BRISBANE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXON, INC. (Exact name of Registrant as specified in its Charter) Delaware 27-5414423 (State or other jurisdiction of i ...

Accelerated Enrollment in Phase 3 ARCHER II Trial on Pace for Completion in Third Quarter 2025 for ANX007, the First Potential Treatment for Dry AMD with GA; Pivotal Topline Data Expected in the Second Half of 2026 Completion of Proof-of-Concept Trial for First-in-Kind Oral C1s Inhibitor ANX1502 in Cold Agglutin Disease Anticipated Mid-2025; Potential to Disrupt the Current Treatment of Antibody-Mediated Autoimmune Diseases $263.7 million in Cash, Cash Equivalents, and Short-term Investments as of March 31, ...

FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study Designed to Broaden Patient and Healthcare Community Experience in North America and Europe, Initiating in Second Quarter 2025 Accelerated Enrollment in Phase 3 ARCHER II Trial on Pace for Completion in Third Quarter 2025 for ANX007, the First Potential Treatment for Dry AMD with GA; Pivotal Topline Data Expected ...

文章核心观点 - 安进公司宣布在2025年周围神经学会年会上展示tanruprubart（原ANX005）的研究成果，该药物在治疗格林 - 巴利综合征（GBS）上比现有标准疗法有更好的效果 [1] 分组1：GBS疾病介绍 - GBS是一种罕见的神经肌肉急症和自身免疫性疾病，由急性自身抗体和经典补体介导的对周围神经的攻击引起，通常发生在感染后，具有急性、进展迅速的特点，治疗干预时间窗窄 [2][6] - 美国和欧洲每年有超过22000人因GBS住院，目前美国尚无获批治疗方法，该疾病给美国医疗系统带来每年数十亿美元的经济成本 [6] 分组2：tanruprubart药物介绍 - tanruprubart是一种首创的单克隆抗体，通过单次输注阻断经典补体级联的起始分子C1q，以阻止GBS急性期的神经炎症和神经损伤，加快整体恢复 [2] - 该药物能在周围和中枢神经系统中停止C1q活性，减少炎症和神经损伤，静脉给药后能几乎立即阻断C1q功能 [3] - 已获得美国食品药品监督管理局的快速通道和孤儿药指定，以及欧洲药品管理局的孤儿药指定 [5] 分组3：会议展示信息 - 会议将进行口头和海报展示，口头报告主题为“IGOS中的比较有效性：ANX005与静脉注射免疫球蛋白或血浆置换治疗格林 - 巴利综合征”，海报展示主题包括“GBS中早期补体抑制与长期结果的关联：客观指标支持tanruprubart（ANX005）疗效”等 [1][3] - 展示的演讲者及时间分别为Eveline Wiegers在5月19日下午3:55 - 4:10（英国夏令时）等 [4] 分组4：安进公司介绍 - 安进生物科学公司正在开发阻止经典补体驱动的神经炎症的疗法，作为首创疗法治疗患有严重神经炎症疾病的数百万人 [7] - 公司专注于靶向经典补体强效炎症途径的起始分子C1q，其产品线涵盖自身免疫、神经退行性和眼科疾病三个治疗领域，旨在满足全球超800万人的未满足需求 [7]

Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial Enrolling Globally BRISBANE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today ...

文章核心观点 介绍Biotech Analysis Central服务及Annexon相关文章情况，吸引投资者订阅服务 分组1：Biotech Analysis Central服务介绍 - 提供众多制药公司深度分析服务 [1] - 每月订阅费用49美元，年订阅计划有33.50%折扣，每年399美元 [1] - 提供两周免费试用 [1] - 投资组包含600多篇生物技术投资文章、10多只中小盘股票模型投资组合及详细分析、实时聊天和一系列分析与新闻报道 [2] 分组2：Annexon相关 - 曾写过关于Annexon的Seeking Alpha文章 [2]